HK1090922A1 - Cgrp receptor antagonists cgrp - Google Patents
Cgrp receptor antagonists cgrpInfo
- Publication number
- HK1090922A1 HK1090922A1 HK06111605.8A HK06111605A HK1090922A1 HK 1090922 A1 HK1090922 A1 HK 1090922A1 HK 06111605 A HK06111605 A HK 06111605A HK 1090922 A1 HK1090922 A1 HK 1090922A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cgrp
- receptor antagonists
- cgrp receptor
- antagonists
- antagonists cgrp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46308903P | 2003-04-15 | 2003-04-15 | |
US51035203P | 2003-10-10 | 2003-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1090922A1 true HK1090922A1 (en) | 2007-01-05 |
Family
ID=33303112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK06111605.8A HK1090922A1 (en) | 2003-04-15 | 2006-10-20 | Cgrp receptor antagonists cgrp |
Country Status (33)
Country | Link |
---|---|
US (6) | US6953790B2 (de) |
EP (2) | EP1638969B1 (de) |
JP (1) | JP3967766B2 (de) |
KR (1) | KR100769030B1 (de) |
CN (1) | CN100384843C (de) |
AR (1) | AR045887A1 (de) |
AT (1) | ATE413400T1 (de) |
AU (1) | AU2004230926B2 (de) |
BR (1) | BRPI0409601A (de) |
CA (1) | CA2522220C (de) |
CL (1) | CL2004000788A1 (de) |
CO (1) | CO5640130A2 (de) |
CY (1) | CY1108714T1 (de) |
DE (1) | DE602004017608D1 (de) |
DK (1) | DK1638969T3 (de) |
EC (1) | ECSP056097A (de) |
ES (1) | ES2314417T3 (de) |
HK (1) | HK1090922A1 (de) |
HR (1) | HRP20080666T3 (de) |
IS (1) | IS2759B (de) |
JO (1) | JO2355B1 (de) |
MA (1) | MA27728A1 (de) |
MX (1) | MXPA05011166A (de) |
NO (1) | NO327655B1 (de) |
NZ (1) | NZ543357A (de) |
PE (1) | PE20050020A1 (de) |
PL (1) | PL1638969T3 (de) |
PT (1) | PT1638969E (de) |
RU (1) | RU2308458C2 (de) |
SI (1) | SI1638969T1 (de) |
TW (1) | TWI314931B (de) |
UA (1) | UA82877C2 (de) |
WO (2) | WO2004092168A1 (de) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7220862B2 (en) | 2002-06-05 | 2007-05-22 | Bristol-Myers Squibb Company | Calcitonin gene related peptide receptor antagonists |
CN100558728C (zh) * | 2002-06-05 | 2009-11-11 | 布里斯托尔-迈尔斯斯奎布公司 | 降钙素基因相关肽受体拮抗剂 |
US7842808B2 (en) | 2002-06-05 | 2010-11-30 | Bristol-Myers Squibb Company | Anti-migraine spirocycles |
CN100572379C (zh) * | 2003-04-15 | 2009-12-23 | 麦克公司 | Cgrp受体拮抗剂 |
GB0310881D0 (en) * | 2003-05-12 | 2003-06-18 | Merck Sharp & Dohme | Pharmaceutical formulation |
CN1842526A (zh) * | 2003-06-26 | 2006-10-04 | 麦克公司 | 苯并二氮杂䓬cgrp受体拮抗剂 |
CA2529227A1 (en) * | 2003-06-26 | 2005-01-06 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
AR046787A1 (es) | 2003-12-05 | 2005-12-21 | Bristol Myers Squibb Co | Agentes antimigrana heterociclicos |
CN101124217A (zh) * | 2004-01-29 | 2008-02-13 | 默克公司 | Cgrp受体拮抗剂 |
BRPI0507971A (pt) * | 2004-02-23 | 2007-07-24 | Tufts College | composto, composição farmacêutica, uso de um composto,método para inibir a atividade proteolìtica de uma enzima de clivagem pós-prolina e remédio empacotado |
TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
WO2006041830A2 (en) * | 2004-10-07 | 2006-04-20 | Merck & Co., Inc. | Cgrp receptor antagonists |
CA2583534A1 (en) * | 2004-10-14 | 2006-04-27 | Merck & Co., Inc. | Cgrp receptor antagonists |
CA2584241A1 (en) | 2004-10-22 | 2006-05-04 | Merck & Co., Inc. | Cgrp receptor antagonists |
US7384930B2 (en) | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7384931B2 (en) * | 2004-11-03 | 2008-06-10 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7449586B2 (en) | 2004-12-03 | 2008-11-11 | Bristol-Myers Squibb Company | Processes for the preparation of CGRP-receptor antagonists and intermediates thereof |
GB2423085C (en) * | 2005-02-11 | 2011-11-09 | Cambridge Entpr Ltd | Ligands for G-protein coupled receptors |
GB2467060B (en) * | 2005-02-11 | 2010-09-01 | Cambridge Entpr Ltd | Ligands for G-protein coupled receptors |
AU2006223236A1 (en) * | 2005-03-14 | 2006-09-21 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
US7834007B2 (en) | 2005-08-25 | 2010-11-16 | Bristol-Myers Squibb Company | CGRP antagonists |
US8168592B2 (en) | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
CN101309704B (zh) | 2005-11-14 | 2012-10-10 | 礼纳特神经系统科学公司 | 针对降钙素基因相关肽的拮抗剂抗体及其使用方法 |
CN100371327C (zh) * | 2005-11-17 | 2008-02-27 | 江苏工业学院 | 2-氨基-6-烷氧基-3-硝基吡啶的一步合成法 |
JP2009515972A (ja) * | 2005-11-18 | 2009-04-16 | メルク エンド カムパニー インコーポレーテッド | スピロラクタムアリールcgrp受容体アンタゴニスト |
EP2007763A2 (de) * | 2006-04-10 | 2008-12-31 | Merck & Co., Inc. | Herstellungsverfahren für ein zwischenprodukt eines heterocyclischen pyridin-cgrp-antagonisten |
WO2007120589A2 (en) * | 2006-04-10 | 2007-10-25 | Merck & Co., Inc. | Process for the preparation of caprolactam cgrp antagonist intermediate |
CN101421266A (zh) | 2006-04-10 | 2009-04-29 | 默克公司 | 制备cgrp拮抗剂的方法 |
JP2009533440A (ja) * | 2006-04-10 | 2009-09-17 | メルク エンド カムパニー インコーポレーテッド | Cgrp拮抗薬塩 |
US7470679B2 (en) | 2006-05-02 | 2008-12-30 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
US7470680B2 (en) * | 2006-05-03 | 2008-12-30 | Bristol-Myers Squibb Company | Constrained compounds as CGRP-receptor antagonists |
CA2650932C (en) * | 2006-05-09 | 2013-01-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
EP2027106A2 (de) * | 2006-06-13 | 2009-02-25 | Vertex Pharmaceuticals Incorporated | Cgrp-rezeptorantagonisten |
US7834000B2 (en) | 2006-06-13 | 2010-11-16 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
US8163737B2 (en) | 2006-06-13 | 2012-04-24 | Vertex Pharmaceuticals Incorporated | CGRP receptor antagonists |
US8227603B2 (en) | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
ES2558517T3 (es) * | 2006-08-02 | 2016-02-04 | Cytokinetics, Inc. | Ciertas entidades químicas, composiciones y métodos que comprenden imidazopirimidinas |
CN101511184A (zh) * | 2006-09-08 | 2009-08-19 | 默克公司 | 用于口服给药cgrp拮抗剂的液体药物制剂 |
MY148544A (en) | 2007-05-23 | 2013-04-30 | Merck Sharp & Dohme | Pyridyl piperidine orexin receptor antagonists |
GB0712392D0 (en) * | 2007-06-26 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
US20090075977A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched mk0974 |
JP2011511792A (ja) * | 2008-02-05 | 2011-04-14 | メルク・シャープ・エンド・ドーム・コーポレイション | Cgrp受容体アンタゴニストのプロドラッグ |
WO2009105348A1 (en) | 2008-02-19 | 2009-08-27 | Merck & Co., Inc. | Imidazobenzazepine cgrp receptor antagonists |
CA2716424C (en) | 2008-03-04 | 2015-04-28 | Pfizer Limited | Methods of treating chronic pain |
US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8143403B2 (en) | 2008-04-11 | 2012-03-27 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
RU2011103170A (ru) * | 2008-06-30 | 2012-08-10 | Мерк Шарп Энд Домэ Корп. (Us) | Твердые дозированные составы телкагепанта калия |
JP2012506379A (ja) * | 2008-10-21 | 2012-03-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 二置換アゼパンオレキシン受容体アンタゴニスト |
US8715715B2 (en) | 2008-11-03 | 2014-05-06 | Nal Pharmaceuticals Ltd. | Dosage form for insertion into the mouth |
AU2010288194B2 (en) | 2009-08-28 | 2013-08-29 | Teva Pharmaceuticals International Gmbh | Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide |
US8314117B2 (en) | 2009-10-14 | 2012-11-20 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
US8669368B2 (en) | 2010-10-12 | 2014-03-11 | Bristol-Myers Squibb Company | Process for the preparation of cycloheptapyridine CGRP receptor antagonists |
TWI522355B (zh) | 2010-11-12 | 2016-02-21 | 默沙東藥廠 | 六氫吡啶酮甲醯胺氮雜茚滿cgrp受體拮抗劑 |
JP2014508170A (ja) * | 2011-03-18 | 2014-04-03 | メルク・シャープ・アンド・ドーム・コーポレーション | ピペリジノンカルボキサミドスピロヒダントインcgrp受容体アンタゴニスト |
US8748429B2 (en) | 2011-04-12 | 2014-06-10 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
AU2012258976B8 (en) | 2011-05-20 | 2017-07-20 | H. Lundbeck A/S | Use of anti-CGRP or anti-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea |
HUE055505T2 (hu) | 2011-05-20 | 2021-11-29 | H Lundbeck As | Anti-CGRP készítmények és alkalmazásuk |
DK2709663T3 (da) | 2011-05-20 | 2019-05-20 | Alderbio Holdings Llc | Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere |
WO2013010015A2 (en) | 2011-07-13 | 2013-01-17 | Cytokinetics, Inc. | Combination als therapy |
AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
RS56556B1 (sr) | 2012-02-27 | 2018-02-28 | Bristol Myers Squibb Co | N- (5s, 6s, 9r) - 5 -amino- 6 - (2, 3 - difluorofenil) -6, 7, 8, 9 - tetrahidro - 5h - ciklohepta [b]piridin-9 -il- 4 - (2 - okso-2, 3 - dihidro - 1h- imidazo [4, 5 -b]piridin - 1 - il) piperidin - 1 - karboksilat, hemisulfatna so |
US9375002B2 (en) | 2012-03-29 | 2016-06-28 | Bayer Intellectual Property Gmbh | 5-aminopyrimidine derivatives and use thereof for combating undesired plant growth |
JP6491669B2 (ja) | 2014-02-05 | 2019-03-27 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | Cgrp活性化合物の錠剤製剤 |
US10556945B2 (en) | 2014-03-21 | 2020-02-11 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
US9896502B2 (en) | 2014-03-21 | 2018-02-20 | Teva Pharmaceuticals International Gmbh | Antagonist antibodies directed against calcitonin gene-related peptide and methods using same |
GB201417707D0 (en) | 2014-10-07 | 2014-11-19 | Viral Ltd | Pharmaceutical compounds |
WO2017001434A1 (en) * | 2015-06-29 | 2017-01-05 | Galderma Research & Development | Cgrp receptor antagonist compounds for topical treatment of skin disorders |
GB201519196D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
GB201519194D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP receptor antagonists |
GB201519195D0 (en) | 2015-10-30 | 2015-12-16 | Heptares Therapeutics Ltd | CGRP Receptor Antagonists |
KR20190066607A (ko) | 2016-09-23 | 2019-06-13 | 테바 파마슈티컬스 인터내셔널 게엠베하 | 불응성 편두통의 치료 |
EP3366286A1 (de) | 2017-02-22 | 2018-08-29 | Johannes Keller | Verbindungen zur behandlung von sepsis |
GB201707938D0 (en) | 2017-05-17 | 2017-06-28 | Univ Sheffield | Compounds |
CN111683937A (zh) | 2018-01-19 | 2020-09-18 | 爱杜西亚药品有限公司 | C5a受体调节剂 |
CN108892635A (zh) * | 2018-09-07 | 2018-11-27 | 江苏工程职业技术学院 | 一种西沙必利关键中间体的制备方法 |
MX2021008267A (es) | 2019-01-08 | 2021-08-05 | H Lundbeck As | Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp. |
AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
KR20230157986A (ko) | 2021-03-02 | 2023-11-17 | 체게에르페 다이어그노스틱스 게엠베하 | 편투통 발생의 치료 및/또는 저감 |
WO2023026205A1 (en) | 2021-08-24 | 2023-03-02 | Cgrp Diagnostics Gmbh | Preventative treatment of migraine |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
WO1996035713A1 (en) | 1995-05-08 | 1996-11-14 | Pfizer, Inc. | Dipeptides which promote release of growth hormone |
AU6211499A (en) * | 1998-09-30 | 2000-04-17 | Merck & Co., Inc. | Benzimidazolinyl piperidines as cgrp ligands |
WO2000018765A1 (fr) | 1998-09-30 | 2000-04-06 | Taisho Pharmaceutical Co., Ltd. | Composes d'isoxazolylthiophene substitue |
CN100558728C (zh) * | 2002-06-05 | 2009-11-11 | 布里斯托尔-迈尔斯斯奎布公司 | 降钙素基因相关肽受体拮抗剂 |
CN100572379C (zh) * | 2003-04-15 | 2009-12-23 | 麦克公司 | Cgrp受体拮抗剂 |
-
2004
- 2004-04-07 JO JO200445A patent/JO2355B1/en active
- 2004-04-09 PL PL04749887T patent/PL1638969T3/pl unknown
- 2004-04-09 DE DE602004017608T patent/DE602004017608D1/de not_active Expired - Lifetime
- 2004-04-09 PT PT04749887T patent/PT1638969E/pt unknown
- 2004-04-09 JP JP2006509818A patent/JP3967766B2/ja not_active Expired - Fee Related
- 2004-04-09 CA CA002522220A patent/CA2522220C/en not_active Expired - Fee Related
- 2004-04-09 RU RU2005135440/04A patent/RU2308458C2/ru not_active IP Right Cessation
- 2004-04-09 WO PCT/US2004/011280 patent/WO2004092168A1/en active Application Filing
- 2004-04-09 DK DK04749887T patent/DK1638969T3/da active
- 2004-04-09 EP EP04749887A patent/EP1638969B1/de not_active Expired - Lifetime
- 2004-04-09 NZ NZ543357A patent/NZ543357A/en not_active IP Right Cessation
- 2004-04-09 BR BRPI0409601-0A patent/BRPI0409601A/pt not_active IP Right Cessation
- 2004-04-09 SI SI200430961T patent/SI1638969T1/sl unknown
- 2004-04-09 EP EP08105721.8A patent/EP2039694B1/de not_active Expired - Lifetime
- 2004-04-09 ES ES04749887T patent/ES2314417T3/es not_active Expired - Lifetime
- 2004-04-09 WO PCT/US2004/010851 patent/WO2004092166A2/en active Application Filing
- 2004-04-09 AT AT04749887T patent/ATE413400T1/de active
- 2004-04-09 AU AU2004230926A patent/AU2004230926B2/en not_active Ceased
- 2004-04-09 KR KR1020057019692A patent/KR100769030B1/ko not_active IP Right Cessation
- 2004-04-09 MX MXPA05011166A patent/MXPA05011166A/es active IP Right Grant
- 2004-04-09 CN CNB2004800161154A patent/CN100384843C/zh not_active Expired - Fee Related
- 2004-04-12 PE PE2004000364A patent/PE20050020A1/es not_active Application Discontinuation
- 2004-04-13 CL CL200400788A patent/CL2004000788A1/es unknown
- 2004-04-13 AR ARP040101238A patent/AR045887A1/es active IP Right Grant
- 2004-04-14 TW TW093110393A patent/TWI314931B/zh not_active IP Right Cessation
- 2004-05-04 US US10/838,835 patent/US6953790B2/en not_active Expired - Lifetime
- 2004-09-04 UA UAA200510685A patent/UA82877C2/uk unknown
-
2005
- 2005-06-14 US US11/152,537 patent/US7235545B2/en not_active Expired - Lifetime
- 2005-09-29 IS IS8055A patent/IS2759B/is unknown
- 2005-10-11 MA MA28550A patent/MA27728A1/fr unknown
- 2005-10-12 EC EC2005006097A patent/ECSP056097A/es unknown
- 2005-10-12 CO CO05104372A patent/CO5640130A2/es active IP Right Grant
- 2005-11-14 NO NO20055375A patent/NO327655B1/no not_active IP Right Cessation
-
2006
- 2006-10-20 HK HK06111605.8A patent/HK1090922A1/xx not_active IP Right Cessation
-
2007
- 2007-03-14 US US11/724,066 patent/US7452903B2/en not_active Expired - Lifetime
-
2008
- 2008-04-09 US US12/082,233 patent/US7534784B2/en not_active Expired - Lifetime
- 2008-12-19 HR HR20080666T patent/HRP20080666T3/xx unknown
-
2009
- 2009-01-15 CY CY20091100053T patent/CY1108714T1/el unknown
- 2009-04-03 US US12/417,911 patent/US7772224B2/en not_active Expired - Lifetime
-
2010
- 2010-07-07 US US12/831,802 patent/US7893052B2/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1090922A1 (en) | Cgrp receptor antagonists cgrp | |
EP1765805A4 (de) | Cgrp-rezeptorantagonisten | |
IL174538A0 (en) | Thrombin receptor antagonists | |
EP1641781A4 (de) | Benzodiazepin-cgrp-rezeptor-antagonisten | |
EP1799672A4 (de) | Cgrp-rezeptorantagonisten | |
EP1814550A4 (de) | N-sulfonylpiperidin-cannabinoid-rezeptor-1-antagonisten | |
AU2003261392A8 (en) | M3muscarinic acetylcholine receptor antagonists | |
TWI346553B (en) | Chemokine receptor antagonists | |
IL172822A0 (en) | Muscarnic acetylcholine receptor antagonists | |
TWI341198B (en) | Hydroisoindoline tachykinin receptor antagonists | |
TWI348467B (en) | Nk1 antagonists | |
IL182355A0 (en) | Thrombin receptor antagonists | |
HK1070887A1 (en) | Tricyclic thrombin receptor antagonists | |
IL175084A0 (en) | Antagonists of the bradykinin b1 receptor | |
EP1912653A4 (de) | Heterozyklische benzodiazepin-cgrp-rezeptor-antagonisten | |
PL378753A1 (pl) | Antagoniści receptora CCR-3 | |
EP1812008A4 (de) | Il-8-rezeptorantagonisten | |
EP1631559A4 (de) | Il-8-rezeptorantagonisten | |
EP1696949A4 (de) | Vegf-rezeptor-antagonisten | |
SG131946A1 (en) | Ccr3 receptor antagonists | |
AU2003287219A8 (en) | Il-8 receptor antagonists | |
ZA200605574B (en) | Hydroisoindoline tachykinin receptor antagonists | |
EP1636230A4 (de) | A1-adenosinrezeptorantagonisten | |
GB0302094D0 (en) | EP4 receptor antagonists | |
SI1534736T1 (sl) | Antagonisti Nogo receptorja |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20150409 |